Trial
NCT02895100
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Protagonist Therapeutics, Inc.
Collaborators
—
Condition
Ulcerative Colitis
Intervention
PTG-100
Why stopped
Data Monitoring Committee discontinued the trial due to futility-based outcome
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-21